Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis - 28/10/16
, Chris Harris a, Julie Morris b, David W. Denning aSummary |
Objectives |
To assess the clinical response and renal toxicity observed in chronic pulmonary aspergillosis (CPA) patients receiving ≥1 short-courses of liposomal amphotericin (LAmB) (AmBisome®) therapy.
Methods |
A retrospective audit of clinical response and renal function was undertaken in 71 CPA patients (41 male) treated with LAmB at the National Aspergillosis Centre, including 20 patients receiving repeated treatment courses or long-term therapy (n = 5).
Results |
Median age was 64 years (range 29–86 years). Treatment indications included respiratory symptoms (n = 33; 46.5%), constitutional symptoms (n = 2; 2.8%) or both (n = 36; 50.7%). 48 patients (73.8%) responded to their first LAmB course. Quality of life (QOL) improvements occurred in 37 (92.5%) of 40 patients with sufficient data available. Response rates for repeated short-courses of LAmB were 76.6%; QOL improvements were observed in 91.7% of treatment courses. All patients on long-term therapy demonstrated a response. 34 (50%) and 17 (25%) patients respectively developed an increased risk of acute kidney injury (AKI) or actual AKI with their first treatment; a significant reduction in geometric mean eGFR was observed and a similar pattern occurred following their second treatment course.
Conclusions |
Whilst CPA is responsive to LAmB, caution should be exercised with repeated courses, if other treatments are available.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Clinical response to the first LAmB course in CPA patients was 74%. |
• | Improvements in QOL in CPA patients after their first LAmB course was 92%. |
• | 50% of CPA patients had an increased risk of AKI with their first LAmB course. |
• | 25% of CPA patients developed AKI with their first LAmB course. |
• | The geometric mean eGFR in CPA patients was reduced post LAmB therapy. |
Keywords : Liposomal amphotericin B, Chronic pulmonary aspergillosis, Aspergillus, Acute kidney injury, Quality of life
Plan
Vol 73 - N° 5
P. 485-495 - novembre 2016 Retour au numéro
Article précédent
- Screening for acute HIV infection in community-based settings: Cost-effectiveness and impact on transmissions
- Martin Hoenigl, Antoine Chaillon, Sanjay R. Mehta, Davey M. Smith, Joshua Graff-Zivin, Susan J. Little
- Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients
- Silvia Park, Kihyun Kim, Jun Ho Jang, Seok Jin Kim, Won Seog Kim, Doo Ryeon Chung, Cheol-In Kang, Kyong Ran Peck, Chul Won Jung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?